These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8122279)

  • 1. Quality assurance programs for immunosuppressive drugs: cyclosporine and beyond.
    Holt DW; Marwaha G; Jones K; Johnston A
    Ther Drug Monit; 1993 Dec; 15(6):472-7. PubMed ID: 8122279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality assessment issues of new immunosuppressive drugs and experimental experience.
    Holt DW; Jones K; Lee T; Stadler P; Johnston A
    Ther Drug Monit; 1996 Aug; 18(4):362-7. PubMed ID: 8857551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Program of external quality control in cyclosporine dosage: summary and analysis from French laboratories].
    Marquet P; Perrin A; Billaud E; Méninat F; Johnston A; Holt DW; Vassault A
    Ann Biol Clin (Paris); 1999 May; 57(3):360-3. PubMed ID: 10377491
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic monitoring of sirolimus: its contribution to optimal prescription.
    Holt DW; Denny K; Lee TD; Johnston A
    Transplant Proc; 2003 May; 35(3 Suppl):157S-161S. PubMed ID: 12742490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12th quality assessment of cyclosporin blood monitoring by 56 Japanese laboratories.
    Takagi H; Uchida K; Takahara S; Takahashi K
    Transplant Proc; 1998 Aug; 30(5):1706-8. PubMed ID: 9723250
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J; Cole E; Cantarovich M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythrocyte-to-plasma distribution ratio of cyclosporine: a useful indicator to predict cyclosporine pharmacokinetics and physiological changes during cyclosporine monitoring.
    Shibata N; Hoshino N; Yamaji A; Park KI; Inoue H; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y
    Transplant Proc; 1996 Jun; 28(3):1313-5. PubMed ID: 8658674
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclosporine A: clinical experience and therapeutic drug monitoring.
    Lindholm A
    Ther Drug Monit; 1995 Dec; 17(6):631-7. PubMed ID: 8588233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A: peak or trough level monitoring in renal transplant recipients?
    Wacke R; Drewelow B; Kundt G; Hehl EM; Bast R; Seiter H
    Transplant Proc; 2001; 33(7-8):3122-3. PubMed ID: 11750342
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling?
    Gaspari F; Caruso R; Cattaneo D; Perico N; Remuzzi G
    Transplant Proc; 2001; 33(7-8):3117-9. PubMed ID: 11750340
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine trough level or 2-hour postdose level monitoring among kidney transplant recipients: Iranian practice.
    Einollahi B; Rostami Z; Teimoori M
    Iran J Kidney Dis; 2012 Sep; 6(5):389-90. PubMed ID: 22976267
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimization of cyclosporine therapy in kidney transplantation.
    Remuzzi G; Perico N; Gaspari F
    Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238
    [No Abstract]   [Full Text] [Related]  

  • 13. FPIA and EMIT methods compared for cyclosporine monitoring in heart transplant patients.
    Fatio R; Sütsch G; Pei P; Follath F; Kiowski W
    Clin Chem; 1998 Mar; 44(3):693-4. PubMed ID: 9510894
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes.
    Kahan BD; Napoli KL; Podbielski J; Hussein I; Katz SH; Van Buren CT
    Transplant Proc; 2001; 33(1-2):1278. PubMed ID: 11267290
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclosporine level: which single-point estimation of drug level is the best?
    Sharma R; Kumar J; Ahmed M; Gupta A; Gulati S; Sharma AP; Bhandari M
    Transplant Proc; 2001; 33(7-8):3124-5. PubMed ID: 11750343
    [No Abstract]   [Full Text] [Related]  

  • 16. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients.
    Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S
    Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379
    [No Abstract]   [Full Text] [Related]  

  • 17. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy.
    Roos K; Gotthardt D; Giese T; Schnitzler P; Stremmel W; Czock D; Eisenbach C
    Liver Transpl; 2014 Sep; 20(9):1106-17. PubMed ID: 24890314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine therapeutic drug monitoring.
    Jensen SA; Dalhoff KP
    Transplant Proc; 2001 Sep; 33(6):3003-5. PubMed ID: 11543826
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.